The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute
Issue link: https://lifescienceleadermag.epubxp.com/i/792774
K E Y W W W.C M O L E A D E R S H I PA W A R D S .C O M LIFESCIENCELEADER.COM THE CMO LEADERSHIP AWARDS 2017 57 CAPABILITIES COMPATIBILITY DEVELOPMENT EXPERTISE RELIABILITY QUALITY 2017 CMO LEADERSHIP AWARDS WINNERS Company Profiles DRUG LIFE CYCLE STAGES: Research & Development: Discovery, Pre- Clinical, Clinical (Phase 1, Phase 2, Phase 3) Drug Substance Production: Primary Process Development, Drug Substance Production Formulated Drug Production: Dosage Form Development SERVICES & CAPABILITIES: injectables, liquids, lyophilized products, peptides, proteins, vaccines, analytical development, protein characterization, formulation development, cell line development, microbial process development, mammalian process development, particle characterization, mass spectrometry "KBI Biopharma's mission is to accelerate the development of innovative discoveries into life- changing biological products. We are honored to be recognized for our leadership in all six cat- egories, as they directly reflect KBI's core values. These values are also shared by the most talented and dedicated professionals in our industry, and I feel very grateful to work alongside many of them, as colleagues and clients, to rapidly advance therapeutic programs for patients." DRUG TYPE: Biopharmaceuticals TIM KELLY President CATEGORIES WON: KBI Biopharma Durham, NC www.kbibiopharma.com Phone: +1 919 479 9898 Contact: Stewart McNaull Email: smcnaull@kbibiopharma.com Key locations: Durham, NC; Boulder, CO, The Woodlands, TX INDIVIDUAL ATTRIBUTE AWARDS: accessible senior management, cultural fit, innovation, on-time, right first time, strength of science DRUG LIFE CYCLE STAGES: Research & Development: Clinical (Phase 1, Phase 2, Phase 3) Drug Substance Production: Primary Process Development, Drug Substance Production SERVICES & CAPABILITIES: aseptic fill/finish, cytotoxic & high potency compounds, generics, vaccines "Our sincere thanks to our customers for reward- ing Novasep in so many categories and for your loyal support. Customer service remains at the core of our day-to-day activities, and we thank our dedicated Project Management team for their key role in developing customer relationships based on teamwork, transparency and mutual trust. Finally we recognize the outstanding contribution of our Quality Assurance team with 3 successful FDA site inspections in 2016." DRUG TYPE: Pharmaceuticals, Biopharmaceuticals JEAN BLÉHAUT President, Synthesis Business Unit CATEGORIES WON: NOVASEP Lyon, France www.novasep.com Phone: +33 437 282 030 Contact: Jean-Baptiste Agnus Email: jean-baptiste@novasep.com Key locations: Le Mans, France; Chasse-sur- Rhône, France; Mourenx, France; Pompey, France; Leverkusen, Germany; Gosselies, Belgium INDIVIDUAL ATTRIBUTE AWARDS: accessible senior management, cultural fit, innovation, on-time, reputation, state-of-the-art, strength of science DRUG LIFE CYCLE STAGES: Research & Development: Discovery, Pre- Clinical, Clinical (Phase 1, Phase 2) Drug Substance Production: Primary Process Development, Drug Substance Production Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging SERVICES & CAPABILITIES: aseptic fill/finish, cytotoxic & high potency compounds, inject- ables, liquids, non-sterile, parenterals: small volume, peptides, proteins, solutions & suspen- sions, sterile, vaccines, process development, cell & virus banking, fermentation, cell culture, purification, formulation "Credit for this recognition goes, first and foremost, to all of our hard-working scientists, engineers, quality systems personnel, and project managers. This acknowledgement from our peers is a great honor and we believe that it reflects our dedication and passion for the science. At Paragon, we are committed to building a world class GMP organiza- tion to support growth initiatives in vaccine and gene-therapy viral vector manufacturing." DRUG TYPE: Biopharmaceuticals PETER BUZY President & CEO CATEGORIES WON: Paragon Bioservices Baltimore, MD paragonbioservices.com Phone: +1 410 975 4050 Contact: Philip Wills Email: pwills@paragonbioservices.com Key locations: Baltimore, MD INDIVIDUAL ATTRIBUTE AWARDS: accessible senior management, innovation, on-time, reputation, strength of science